-
A Significant Advance in RRP Treatment: Papizimeos Reaches New Standard of Care Status
NASDAQ: $PGEN A landmark development in the treatment of Recurrent Respiratory Papillomatosis (RRP) has recently been announced, marking a potential shift in clinical practice for thousands of patients worldwide. A new expert consensus, formally published in the prestigious medical journal, The Laryngoscope, strongly recommends Papizimeos (zopapogene imadenovec) as the new standard of care for first-line…